[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638139":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":163,"collaborators":24,"id":165,"slug":24,"hasResults":166,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":24,"eligibilityCriteria":170,"healthyVolunteers":166,"sex":171,"minAge":172,"maxAge":24,"enrollmentInfo":173,"targetDuration":24,"studyType":176,"phases":177,"briefSummary":179,"conditions":180,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},{"fullName":5,"class":6},"Relay Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: RLY-8161 for participants with advanced NRAS-mutant solid tumors","EXPERIMENTAL","Multiple doses of RLY-8161 for oral administration",[13],"Drug: RLY-8161",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2: RLY-8161 for participants with advanced NRAS-mutant solid tumors","Oral doses of RLY-8161 as determined during Part 1 Dose Escalation",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","RLY-8161","RLY-8161 is an NRAS-selective inhibitor",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Relay Therapeutics, Inc","CONTACT","617-322-0731","ClinicalTrials@relaytx.com",[32,50,64,79,94,105,119,133,148],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of California, Los Angeles","RECRUITING","Los Angeles","California","90095","United States",{"type":40,"coordinates":41},"Point",[42,43],-118.24368,34.05223,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":48,"phoneExt":24,"email":49},"Bartosz Chmielowski, MD","310-794-4655","bchmielowski@mednet.ucla.edu",{"facility":51,"status":34,"city":52,"state":36,"zip":53,"country":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"University of California, San Francisco","San Francisco","94143",{"type":40,"coordinates":55},[56,57],-122.41942,37.77493,{"lat":57,"lon":56},[60],{"name":61,"role":28,"phone":62,"phoneExt":24,"email":63},"Sonia C Martinez","415-714-4484","Sonia.ContrerasMartinez@ucsf.edu",{"facility":65,"status":34,"city":66,"state":67,"zip":68,"country":38,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"University of Colorado Hospital","Aurora","Colorado","80045",{"type":40,"coordinates":70},[71,72],-104.83192,39.72943,{"lat":72,"lon":71},[75],{"name":76,"role":28,"phone":77,"phoneExt":24,"email":78},"Meagan Brander","303-724-8869","MAEGAN.BRANDER@CUANSCHUTZ.EDU",{"facility":80,"status":34,"city":81,"state":82,"zip":83,"country":38,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":40,"coordinates":85},[86,87],-71.05977,42.35843,{"lat":87,"lon":86},[90],{"name":91,"role":28,"phone":92,"phoneExt":24,"email":93},"Ryan Sullivan, MD","617-243-5480","RSULLIVAN7@mgh.harvard.edu",{"facility":95,"status":34,"city":81,"state":82,"zip":96,"country":38,"cosmosGeoPoint":97,"geoPoint":99,"contacts":100},"Dana Farber Cancer Institute","02215",{"type":40,"coordinates":98},[86,87],{"lat":87,"lon":86},[101],{"name":102,"role":28,"phone":103,"phoneExt":24,"email":104},"Linnea Drew","617-632-6704","Linneam_drew@dfci.harvard.edu",{"facility":106,"status":34,"city":107,"state":108,"zip":109,"country":38,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"START Midwest, LLC","Grand Rapids","Michigan","49546",{"type":40,"coordinates":111},[112,113],-85.66809,42.96336,{"lat":113,"lon":112},[116],{"name":24,"role":28,"phone":117,"phoneExt":24,"email":118},"616-954-5554","hopeteam@startresearch.com",{"facility":120,"status":34,"city":121,"state":121,"zip":122,"country":38,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":40,"coordinates":124},[125,126],-74.00597,40.71427,{"lat":126,"lon":125},[129],{"name":130,"role":28,"phone":131,"phoneExt":24,"email":132},"Monica Chen, MD","646-888-5108","ChenM9@mskcc.org",{"facility":134,"status":34,"city":135,"state":136,"zip":137,"country":38,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Sarah Cannon Research Institute Oncology Partners","Nashville","Tennessee","37203",{"type":40,"coordinates":139},[140,141],-86.78444,36.16589,{"lat":141,"lon":140},[144],{"name":145,"role":28,"phone":146,"phoneExt":24,"email":147},"ASKSarah","877-MY-1-SCRI (691-7274)","ASKSARAH@scresearch.net",{"facility":149,"status":34,"city":150,"state":151,"zip":152,"country":38,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"NEXT Virginia","Fairfax","Virginia","22031",{"type":40,"coordinates":154},[155,156],-77.30637,38.84622,{"lat":156,"lon":155},[159],{"name":160,"role":28,"phone":161,"phoneExt":24,"email":162},"Paolo Umayam","703-783-4546","pumayam@nextoncology.com",{"type":164,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100638139",false,"NCT07584226","A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors","A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Histologically confirmed diagnosis of unresectable Stage III or IV melanoma or other solid tumor.\n* Disease is refractory to standard therapy (including targeted therapy), participant is intolerant of standard therapy, or participant has declined standard therapy.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* One or more documented primary oncogenic NRAS mutation(s).\n\nExclusion Criteria:\n\n* Known activating KRAS, HRAS, or BRAF mutation or known alterations in other driver oncogenes.\n* Prior treatment with ERK, MEK, RAF, or RAS targeting agents or any agent whose mechanism of action is to inhibit the RAS-MAPK pathway.\n* For participants with melanoma: lactate dehydrogenase (LDH) \\>2×ULN.\n* Central nervous system (CNS) metastases that are associated with progressive neurologic symptoms or require ongoing corticosteroids to control the CNS disease.","ALL","18 Years",{"count":174,"type":175},35,"ESTIMATED","INTERVENTIONAL",[178],"PHASE1","This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.",[181,182,183,184,185,186,187,188,189,190,191],"Advanced NRAS-Mutant Melanoma","Advanced NRAS-Mutant Solid Tumors","NRAS Mutation","NRAS G12D","NRAS G13R","NRAS G13D","NRAS G12V","NRAS Q61R","NRAS Q61K","NRAS Q61L","NRAS Q61H","2026-06-30",{"date":194,"type":195},"2026-07-02","ACTUAL",{"date":197,"type":195},"2026-03-09",{"date":199,"type":175},"2029-12-31",{"name":5,"class":6},9]